Airuike Dacomitinib cas 1110813-31-4
1 Inquiries
1110813-31-4
Analytical Reagent
99%
qingdao
AIRUIKE
1kg
2024-09-17
api,Intermediates,Organic Chemistry,Inorganic Chemistry,Daily Chemicals,Cosmetic Raw Materals
-
Product Description
-
Seller Information
-
Inquiry History
-
DescriptionECHEMI Editorial ReferenceDacomitinib is a specific and irreversible inhibitor of the ERBB family of kinases with IC50s of 6 nM, 45.7 nM and 73.7 nM for EGFR, ERBB2, and ERBB4, respectively.
Dacomitinib is a member of the class of quinazolines that is 7-methoxyquinazoline-4,6-diamine in which the amino group at position 4 is substituted by a 3-chloro-4-fluorophenyl group and the amino group at position 6 is substituted by an (E)-4-(piperidin-1-yl)but-2-enoyl group. It has a role as an epidermal growth factor receptor antagonist and an antineoplastic agent. It is a member of quinazolines, a member of piperidines, an enamide, a member of monochlorobenzenes, a member of monofluorobenzenes, a tertiary amino compound, a secondary amino compound and a secondary carboxamide.|Dacomitinib, designed as (2E)-N-16-4-(piperidin-1-yl) but-2-enamide, is an oral highly selective quinazalone part of the second-generation tyrosine kinase inhibitors which are characterized by the irreversible binding at the ATP domain of the epidermal growth factor receptor family kinase domains. Dacomitinib was developed by Pfizer Inc and approved by the FDA on September 27, 2018. Some evidence in the literature suggests the therapeutic potential of dacomitinib in the epithelial ovarian cancer model, although further investigations are needed.|Dacomitinib is a multi-kinase receptor inhibitor used in the therapy of cases of non-small cell lung cancer that harbor activating mutations in the epidermal growth factor receptor gene (EGFR). Dacomitinib is associated with high rate of transient serum aminotransferase elevations during therapy but has not been linked to instances of clinically apparent acute liver injury.Basic Info-
Product Name:
Dacomitinib
Other Name:2-Butenamide,N-[4-[(3-chloro-4-fluorophenyl)amino]-7-methoxy-6-quinazolinyl]-4-(1-piperidinyl)-,(2E)-;(2E)-N-[4-[(3-Chloro-4-fluorophenyl)amino]-7-methoxy-6-quinazolinyl]-4-(1-piperidinyl)-2-butenamide;Dacomitinib;PF 00299804;PF 299804;PF 299;1006885-28-4
CAS No.:1110813-31-4
Molecular Formula:C24H25ClFN5O2
InChIKeys:InChIKey=LVXJQMNHJWSHET-AATRIKPKSA-N
Molecular Weight:469.9390032
Exact Mass:469.94
EC Number:-0
UNII:2XJX250C20
DSSTox ID:DTXSID50149493
ATC Code:L01EB07|L - Antineoplastic and immunomodulating agents
HScode:29335990
Categories:
Characteristics-
PSA:
79.4
XLogP3:4.4
Density:1.3±0.1 g/cm3
Melting Point:184-187 ºC
Boiling Point:665.7±55.0°C at 760 mmHg
Flash Point:356.4±31.5 °C
Refractive Index:1.663
Water Solubility:<1 mg/mL
Hazard IdentificationClassification of the substance or mixture
no data available
GHS label elements, including precautionary statements
Pictogram(s) no data available Signal word no data available
Hazard statement(s) no data available
Precautionary statement(s) Prevention no data available
Response no data available
Storage no data available
Disposal no data available
Other hazards which do not result in classification
no data available
Handling and StoragePrecautions for safe handling
Handling in a well ventilated place. Wear suitable protective clothing. Avoid contact with skin and eyes. Avoid formation of dust and aerosols. Use non-sparking tools. Prevent fire caused by electrostatic discharge steam.
Conditions for safe storage, including any incompatibilities
Store the container tightly closed in a dry, cool and well-ventilated place. Store apart from foodstuff containers or incompatible materials.
-
-
Seller Information
-
Business Type:
Trader
-
Main Products:
api,Intermediates,Organic Chemistry,Inorganic Chemistry,Daily Chemicals,Cosmetic Raw Materals
-
Location:
Huangdao District, Qingdao City, Shandong Province (formerly Room 606-2, Building 1, No. 10 Beijing Road, Jiaonan City)
-
Payment Terms:
TT against copy of documents,D/P,D/A,TT against B/L draft before shipment,100% TT in advance
-
Average lead Time:
15
-
Total Annual Revenue:
$5 million-$10 million
-
Total Employees:
51-100
-
Year of Establishment:
2023
-
Certifications:
Credit rating certificate,Hazardous Chemicals Business License
-
-
Inquiry History1 Inquiries
Country Product Purchase Quantity Date Posted
Israel
IDO HANAN
1 G Jun 26, 2026 Post an enquiry for this product
- Hot Searches
- propylene glycol prices
- where do i get reta
- hydrocloric acid sds
- trimethylamine market
- xylene for sale
- conductive silicone rubber market
- kalium oxide
- best place to buy research tirzepatide
- acrylonitrile butadiene styrene price
- bioglutide for sale
- 85559-46-2 price
- solvent naphtha suppliers